Company: MBIO
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001410578-25-000028
Chunk: 241

Company: MUSTANG BIO, INC.
Filing Date: 2025-01-15
Form: S-1
Chunk 241
---
 Hutchinson Cancer Center - CD20          | ​                | ​                               | 1,254 | ​ | ​ | 1,987 |
| St. Jude Children’s Research Hospital - XSCID | ​                | ​                               |   637 | ​ | ​ |   508 |
| Leiden University Medical Center - RAG1 SCID  | ​                | ​                               |   350 | ​ | ​ |   505 |
| Mayo Clinic                                   | ​                | ​                               |   551 | ​ | ​ |   968 |
| Total                                         | ​                | $                               | 4,162 | ​ | $ | 6,989 |

City of Hope

CD123 (MB-102) Clinical Research Support Agreement

In February 2017, the Company entered into a Clinical Research Support Agreement for CD123 (the “CD123 CRA”). Pursuant to the terms of the CD123 CRA the Company made an upfront payment of $ and will contribute an additional $ million per patient in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $ million over pertaining to the clinical development of CD123. For the years ended December 31, 2023 and 2022, the Company recorded $ and $ million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. In May 2023, the Company terminated the CD123 License and associated Clinical Research Support Agreement.

F-15

IL13Rα2 (MB-101) Clinical Research Support Agreements In February 2017, the Company entered into a Clinical Research Support Agreement for IL13Rα2 (the “IL13Rα2 CRA”). Pursuant to the terms of the IL13Rα2 CRA the Company made an upfront payment of approximately $ 9,300and will contribute an additional $ 0.1million related to patient costs in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $ 0.2million over three yearspertaining to the clinical development of IL13Rα2. For the years ended December 31, 2023 and 2022, the Company recorded $ 1.1million and $ 1.5million, respectively, in research and development expenses under the IL13Rα2 CRA in the Statements of Operations pursuant to the terms of this agreement. In October 2020, the Company entered into a Clinical Research Support Agreement for the IL